Joost H. van den Berg

Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma

Maartje W. Rohaan, Troels Holz Borch, Joost H. van den Berg et al. · New England Journal of Medicine · 2022 · 536 citations · Full text

Medicine, Immunology, Oncology +17

Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPα axis and a target for cancer immunotherapy

Meike E. W. Logtenberg, J.H. Marco Jansen, Matthijs Raaben et al. · Nature Medicine · 2019 · 242 citations · Full text

Life Sciences, Molecular Biology, Oncology +13

Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up

Joost H. van den Berg, Bianca Heemskerk, Nienke van Rooij et al. · Journal for ImmunoTherapy of Cancer · 2020 · 197 citations · Full text

Life Sciences, Immunology, Oncology +17

Case Report of a Fatal Serious Adverse Event Upon Administration of T Cells Transduced With a MART-1-specific T-cell Receptor

Joost H. van den Berg, Raquel Gomez-Eerland, B. van de Wiel et al. · Molecular Therapy · 2015 · 110 citations · Full text

Life Sciences, Immunology, Oncology +17

Autotaxin impedes anti-tumor immunity by suppressing chemotaxis and tumor infiltration of CD8+ T cells

Elisa Matas-Rico, Elselien Frijlink, Irene van der Haar Àvila et al. · Cell Reports · 2021 · 76 citations · Full text

Medicine, Immunology, Oncology +17